336 results found
Foust A, 2023, Voltage-sensitive optical probes for measuring cell membrane potentials: An update and applications to ‘non-excitable’ cells, Bioelectricity, ISSN: 2576-3105
Folcher A, Gordienko D, Iamshanova O, et al., 2023, NALCN-mediated sodium influx confers metastatic prostate cancer cell invasiveness., EMBO J, Vol: 42
There is growing evidence that ion channels are critically involved in cancer cell invasiveness and metastasis. However, the molecular mechanisms of ion signaling promoting cancer behavior are poorly understood and the complexity of the underlying remodeling during metastasis remains to be explored. Here, using a variety of in vitro and in vivo techniques, we show that metastatic prostate cancer cells acquire a specific Na+ /Ca2+ signature required for persistent invasion. We identify the Na+ leak channel, NALCN, which is overexpressed in metastatic prostate cancer, as a major initiator and regulator of Ca2+ oscillations required for invadopodia formation. Indeed, NALCN-mediated Na+ influx into cancer cells maintains intracellular Ca2+ oscillations via a specific chain of ion transport proteins including plasmalemmal and mitochondrial Na+ /Ca2+ exchangers, SERCA and store-operated channels. This signaling cascade promotes activity of the NACLN-colocalized proto-oncogene Src kinase, actin remodeling and secretion of proteolytic enzymes, thus increasing cancer cell invasive potential and metastatic lesions in vivo. Overall, our findings provide new insights into an ion signaling pathway specific for metastatic cells where NALCN acts as persistent invasion controller.
Djamgoz MBA, Levin M, 2023, Bioelectricity: A Multifaceted Discipline, and a Multifaceted Issue!, Bioelectricity, Vol: 5, ISSN: 2576-3105
Djamgoz MBA, Levin M, 2022, Another Leap Forward for Bioelectricity, BIOELECTRICITY, Vol: 4, Pages: 189-189, ISSN: 2576-3105
Djamgoz MBA, Levin M, 2022, Bioelectricity: An Update, BIOELECTRICITY, Vol: 4, Pages: 135-135, ISSN: 2576-3105
Djamgoz MBA, 2022, Bioelectricity Industry News, BIOELECTRICITY, Vol: 4, Pages: 186-188, ISSN: 2576-3105
Yerlikaya S, Djamgoz MBA, 2022, Oleamide, a Primary Fatty Acid Amide: Effects on Ion Channels and Cancer, BIOELECTRICITY, Vol: 4, Pages: 136-144, ISSN: 2576-3105
Djamgoz MBA, 2022, Combinatorial Therapy of Cancer: Possible Advantages of Involving Modulators of Ionic Mechanisms, CANCERS, Vol: 14
Qiu S, Fraser SP, Pires W, et al., 2022, Anti-invasive effects of minoxidil on human breast cancer cells: combination with ranolazine, CLINICAL & EXPERIMENTAL METASTASIS, Vol: 39, Pages: 679-689, ISSN: 0262-0898
Djamgoz MBA, 2022, Rosalind Franklin Society: Mary Ann Liebert Award in Science (2021), BIOELECTRICITY, Vol: 4, Pages: 133-133, ISSN: 2576-3105
Djamgoz MBA, Jentzsch V, 2022, Integrative management of pancreatic cancer (PDAC): emerging complementary agents and modalities, Nutrition and Cancer: an international journal, Vol: 74, Pages: 1139-1162, ISSN: 0163-5581
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease. The standard first-line treatment for PDAC is gemcitabine chemotherapy which, unfortunately, offers only limited chance of a lasting cure. This review further evaluates the hypothesis that the effectiveness of gemcitabine can be improved by combining it with evidence-based complementary measures. Previously, supported by clinical trial data, we suggested that a number of dietary factors and nutraceuticals can be integrated with gemcitabine therapy. Here, we evaluate a further 10 agents for which no clinical trials have (yet) been carried out but there are promising data from in vivo and/or in vitro studies including experiments involving combined treatments with gemcitabine. Two groups of complementary agents are considered: Dietary factors (resveratrol, epigallocatechin gallate, vitamin B9, capsaicin, quercetin and sulforaphane) and nutraceutical agents (artemisinin, garcinol, thymoquinone and emodin). In addition, we identified seven promising agents for which there is currently only basic (mostly in vitro) data. Finally, as a special case of combination therapy, we highlighted synergistic drug combinations involving gemcitabine with “repurposed” aspirin or metformin. We conclude overall that integrated management of PDAC currently is likely to produce the best outcome for patients and for this a wide range of complementary measures is available.
Levin M, Djamgoz MBA, 2022, Bioelectricity: From Endogenous Mechanisms to Opportunities in Synthetic Bioengineering, BIOELECTRICITY, Vol: 4, Pages: 1-2, ISSN: 2576-3105
Fraser SP, Onkal R, Theys M, et al., 2022, Neonatal Na(V)1.5 channels: pharmacological distinctiveness of a cancer-related voltage-gated sodium channel splice variant, BRITISH JOURNAL OF PHARMACOLOGY, Vol: 179, Pages: 473-486, ISSN: 0007-1188
Djamgoz MBA, 2022, Ion Transporting Proteins and Cancer: Progress and Perspectives, TARGETS OF CANCER DIAGNOSIS AND TREATMENT, Vol: 183, Pages: 251-277, ISSN: 0303-4240
Djamgoz MBA, 2021, Comments on: Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer, INTERNATIONAL JOURNAL OF CANCER, Vol: 150, Pages: 1212-1213, ISSN: 0020-7136
Djamgoz MBA, Pchelintseva E, 2021, Mechanosensitive Ion Channels and Stem Cell Differentiation, BIOELECTRICITY, Vol: 3, Pages: 249-254, ISSN: 2576-3105
Djamgoz MBA, 2021, 3rd International Meeting on Cancer and Ion Channels September 16-18, 2021; Istanbul Medipol University, Kavacik, Istanbul, Turkey, BIOELECTRICITY, Vol: 3, Pages: 292-293, ISSN: 2576-3105
Fraser SP, Tesi A, Bonito B, et al., 2021, Potassium Channel Blockage and Invasiveness of Strongly Metastatic Prostate and Breast Cancer Cells, BIOELECTRICITY, Vol: 3, Pages: 215-220, ISSN: 2576-3105
Djamgoz MBA, Levin M, 2021, Bioelectricity Is the Bridge Where Cancer Meets Neuroscience, BIOELECTRICITY, Vol: 3, Pages: 159-160, ISSN: 2576-3105
Lastraioli E, Fraser SP, Guzel RM, et al., 2021, Neonatal Nav1.5 protein expression in human colorectal cancer: immunohistochemical characterization and clinical evaluation, Cancers, Vol: 13, Pages: 1-14, ISSN: 2072-6694
Voltage-gated Na+ channels (VGSCs) are expressed widely in human carcinomas and play a significant role in promoting cellular invasiveness and metastasis. However, human tissue-based studies and clinical characterization are lacking. In several carcinomas, including colorectal cancer (CRCa), the predominant VGSC is the neonatal splice variant of Nav1.5 (nNav1.5). The present study was designed to determine the expression patterns and clinical relevance of nNav1.5 protein in human CRCa tissues from patients with available clinicopathological history. The immunohistochemistry was made possible by the use of a polyclonal antibody (NESOpAb) specific for nNav1.5. The analysis showed that, compared with normal mucosa, nNav1.5 expression occurred in CRCa samples (i) at levels that were significantly higher and (ii) with a pattern that was more delineated (i.e., apical/basal or mixed). A surprisingly high level of nNav1.5 protein expression also occurred in adenomas, but this was mainly intracellular and diffuse. nNav1.5 showed a statistically significant association with TNM stage, highest expression being associated with TNM IV and metastatic status. Interestingly, nNav1.5 expression co-occurred with other biomarkers associated with metastasis, including hERG1, KCa3.1, VEGF-A, Glut1, and EGFR. Finally, univariate analysis showed that nNav1.5 expression had an impact on progression-free survival. We conclude (i) that nNav1.5 could represent a novel clinical biomarker (‘companion diagnostic’) useful to better stratify CRCa patients and (ii) that since nNav1.5 expression is functional, it could form the basis of anti-metastatic therapies including in combination with standard treatments.
Phillips JA, Hutchings C, Djamgoz MBA, 2021, Clinical Potential of Nerve Input to Tumors: A Bioelectricity Perspective, BIOELECTRICITY, Vol: 3, Pages: 14-26, ISSN: 2576-3105
Djamgoz MBA, Levin M, 2021, Call for Special Issue Papers: The Bioelectricity of Connective TissueCells and their Environments, BIOELECTRICITY, Vol: 3, Pages: 2-2, ISSN: 2576-3105
Firmenich L, Djamgoz MBA, 2020, Society of General Physiologists Symposium on "Ion Channels and Transporters in Immunity, Inflammation and Antitumor Immunity" (held online on September 11, 2020), BIOELECTRICITY, Vol: 2, Pages: 418-423, ISSN: 2576-3105
Hutchings C, Phillips JA, Djamgoz MBA, 2020, Nerve input to tumours: Pathophysiological consequences of a dynamic relationship, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, Vol: 1874, ISSN: 0304-419X
Jentzsch V, Davis JAA, Djamgoz MBA, 2020, Pancreatic Cancer (PDAC): introduction of evidence-based complementary measures into integrative clinical management, Cancers, Vol: 12, Pages: 1-62, ISSN: 2072-6694
The most common form of pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC), which comprises some 85% of all cases. Currently, this is the fourth highest cause of cancer mortality worldwide and its incidence is rising steeply. Commonly applied clinical therapies offer limited chance of a lasting cure and the five-year survival rate is one of the lowest of the commonly occurring cancers. This review cultivates the hypothesis that the best management of PDAC would be possible by integrating ‘western’ clinical medicine with evidence-based complementary measures. Protecting the liver, where PDAC frequently first spreads, is also given some consideration. Overall, the complementary measures are divided into three groups: dietary factors, nutraceutical agents and lifestyle. In turn, dietary factors are considered as general conditioners, multi-factorial foodstuffs and specific compounds. The general conditioners are alkalinity, low-glycemic index and low-cholesterol. The multi-factorial foodstuffs comprise red meat, fish, fruit/vegetables, dairy, honey and coffee. The available evidence for the beneficial effects of the specific dietary and nutraceutical agents was considered at four levels (in order of prominence): clinical trials, meta-analyses, in vivo tests and in vitro studies. Thus, 9 specific agents were identified (6 dietary and 3 nutraceutical) as acceptable for integration with gemcitabine chemotherapy, the first-line treatment for pancreatic cancer. The specific dietary agents were the following: Vitamins A, C, D and E, genistein and curcumin. As nutraceutical compounds, propolis, triptolide and cannabidiol were accepted. The 9 complementary agents were sub-grouped into two with reference to the main ‘hallmarks of cancer’. Lifestyle factors covered obesity, diabetes, smoking, alcohol and exercise. An integrative treatment regimen was devised for the management of PDAC patients. This involved combining first-line gemcitabine chem
Djamgoz MBA, 2020, What Is Life? By Paul Nurse, BIOELECTRICITY, Vol: 2, Pages: 314-315, ISSN: 2576-3105
Djamgoz MBA, Levin M, 2020, Bioelectricity: A Quick Reminder of a Fast-Advancing Discipline!, BIOELECTRICITY, Vol: 2, Pages: 208-209, ISSN: 2576-3105
Schofield Z, Meloni GN, Tran P, et al., 2020, Correction to ‘Bioelectrical understanding and engineering of cell biology’, Journal of the Royal Society Interface, Vol: 17, Pages: 1-1, ISSN: 1742-5662
Rizaner N, Uzun S, Fraser SP, et al., 2020, Riluzole: Anti-invasive effects on rat prostate cancer cells under normoxic and hypoxic conditions, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, Vol: 127, Pages: 254-264, ISSN: 1742-7835
Schofield Z, Meloni GN, Tran P, et al., 2020, Bioelectrical understanding and engineering of cell biology, Journal of the Royal Society Interface, Vol: 17, Pages: 1-8, ISSN: 1742-5662
The last five decades of molecular and systems biology research have provided unprecedented insights into the molecular and genetic basis of many cellular processes. Despite these insights, however, it is arguable that there is still only limited predictive understanding of cell behaviours. In particular, the basis of heterogeneity in single-cell behaviour and the initiation of many different metabolic, transcriptional or mechanical responses to environmental stimuli remain largely unexplained. To go beyond the status quo, the understanding of cell behaviours emerging from molecular genetics must be complemented with physical and physiological ones, focusing on the intracellular and extracellular conditions within and around cells. Here, we argue that such a combination of genetics, physics and physiology can be grounded on a bioelectrical conceptualization of cells. We motivate the reasoning behind such a proposal and describe examples where a bioelectrical view has been shown to, or can, provide predictive biological understanding. In addition, we discuss how this view opens up novel ways to control cell behaviours by electrical and electrochemical means, setting the stage for the emergence of bioelectrical engineering.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.